New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER
While peanut allergy therapies from Aimmune and DBV Technologies are locked in a race to the finish line, influential cost-effectiveness watchdog ICER has determined that neither therapy offers superior net health benefit compared to strict peanut avoidance, in a final report published on Wednesday.
Traditionally, peanut allergies are managed by avoidance, but the threat of accidental exposure cannot be nullified.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.